Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • DanFrost
    Member
    • Dec 2011
    • 21

    #1

    Is anyone doing tertiary analysis of their DNASeq data?

    Hello!

    I am new here and just trying to get a sense of what everyone is up to. From reading through pages and pages of this forum, I noticed that I didn't see a lot of threads about the statistical analysis or classification of DNA Seq variants.

    Anyone out there doing this kind of work?



    Cheers,

    Dan
  • adaptivegenome
    Super Moderator
    • Nov 2009
    • 436

    #2
    Moved to "General" since this is not a specific question. And yes, many people on the board actively debate the best way to identify true variation from errors arising from sequencing, mapping, etc.

    Comment

    • DanFrost
      Member
      • Dec 2011
      • 21

      #3
      Ahh, thank you so much for moving this to the proper place.

      I have experience with collapsing methods for both common and rare variant burden, but not much outside of that for statistical analysis of variant results.

      Comment

      • NextGenSeq
        Senior Member
        • Apr 2009
        • 482

        #4
        For determining whether a novel SNP is a potential mutation PolyPhen is pretty good



        Last edited by NextGenSeq; 01-05-2012, 09:55 AM.

        Comment

        • jjohnson
          Member
          • Aug 2009
          • 20

          #5
          We use several tools to call, classify, assign confidence, and annotate. A good place to start is the GATK website. The GATK calls and integrates variant annotation via SNPEff as well as provides a wealth of info per SNP to help you ascribe a confidence to the call. For comparative analysis we have looked into PLINK/SEQ from Harvard and Goldenhelix (Commercial), and other popular tools for annotation are annovar and Variant Effect predictor from ENSEMBL. In addition to PolyPhen, SIFT is a nice tool/database as well.
          Justin H. Johnson | Twitter: @BioInfo | LinkedIn: http://bit.ly/LIJHJ | EdgeBio

          Comment

          • DanFrost
            Member
            • Dec 2011
            • 21

            #6
            Justin - thanks for the info. Full disclosure and funny coincidence - I work for Golden Helix!

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
              by SEQadmin2



              CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

              Despite this, “CRISPR helped turn genome editing from a specialized technique into
              ...
              07-31-2026, 11:01 AM
            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, Today, 07:41 AM
            0 responses
            9 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 08-03-2026, 10:13 AM
            0 responses
            23 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-31-2026, 02:55 AM
            0 responses
            38 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            25 views
            0 reactions
            Last Post SEQadmin2  
            Working...